Kyle leads BroadOak Capital Partners' M&A advisory practice and built the firm's San Francisco office after joining in 2011, bringing a background focused specifically on life sciences tools and diagnostics—he previously led that team at Canaccord Genuity, where he completed over $1.4 billion in life sciences transactions, adding another $700 million earlier at RBC Capital Markets, all backed by a B.S., J.D., and MBA from the University of Oklahoma. He also sits on the advisory board of Slone Partners and the board of Techcyte, giving him ties to leadership and company-building in life sciences that go beyond deal-making alone.